T cell receptor recognizing FP-01.1 peptide–MHC complexes (TCR-FP-01.1)

The T cell receptor (TCR) recognizing FP-01.1 peptide–MHC complexes is a specialized immune receptor that plays a critical role in the targeted immunotherapy of cancer. FP-01.1 is a synthetic peptide derived from a tumor-associated antigen, often utilized in peptide-based vaccines to stimulate the immune system. When this peptide is processed and presented by Major Histocompatibility Complex (MHC) molecules, typically HLA-A*02:01, it is recognized by specific TCRs on the surface of CD8+ T cells. This recognition event is the primary signal for T cell activation, leading to the expansion of a T cell population capable of specifically lysing tumor cells that present the same peptide. In a clinical context, this TCR-peptide-MHC interaction is the fundamental mechanism behind the efficacy of FP-01.1-based immunotherapies, aiming to harness the patient's own immune system to combat malignancies. Monitoring the activity and frequency of T cells bearing these specific TCRs serves as a key biomarker for evaluating the immunogenicity and therapeutic potential of the vaccine.

Other names

FP-01.1-specific T-cell receptorTCR recognizing FP-01.1FP-01.1 peptide-HLA complex receptor

The FP-01.1 peptide is a therapeutic vaccine component designed to be presented by Major Histocompatibility Complex (MHC) molecules on the surface of cells. The T cell receptor (TCR) specifically recognizes this FP-01.1 peptide–MHC complex, triggering the activation and proliferation of antigen-specific cytotoxic T lymphocytes (CTLs). These activated T cells then identify and eliminate tumor cells expressing the target antigen, thereby mounting an anti-tumor immune response.